Original articleAdenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminase†
References (24)
- et al.
Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
Lancet
(1972) Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside: a basis for a direct toxic effect of an analog of adenosine
J Biol Chem
(1979)- et al.
Characteristics of an aminohydrolase distinct from adenosine deaminase in cultured human lymphoblasts
Biochem Biophys Acta
(1981) - et al.
Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient severe combined immunodeficiency
Clin Chim Acta
(1981) Red blood cell adenosine deaminase deficiency in a “healthy” !Kung individual [Letter]
Lancet
(1973)Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase: overview, genetic heterogeneity and therapy
Birth Defects
(1983)Metabolic aspects of immunodeficiency disease
Semin Hematol
(1980)- et al.
Dipyridamole and intravenous deoxycytidine therapy in a patient with adenosine deaminase deficiency
Birth Defects
(1983) - et al.
Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase
N Engl J Med
(1987) - et al.
Adenosineresistant Chinese hamster fibroblast variants with hyperactive adenosine-deaminase: an analysis of the protection against exogenous adenosine afforded by increased activity of the deamination pathway
J Cell Physiol
(1984)
In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in an adenosine deaminase deficient patient
J Clin Invest
(1979)
Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency
Proc Natl Acad Sci USA
(1978)
Cited by (186)
Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review
2023, Materials Today ChemistryPoly(ethylene glycol) based biomaterials
2023, Handbook of Polymers in MedicineImprovement of stability and in vivo antioxidant effect of human glutathione peroxidase mutant by PEGylation
2021, International Journal of PharmaceuticsPolymer-enhanced biomacromolecules
2020, Progress in Polymer ScienceCitation Excerpt :In 1990, Adagen was the first PEGylated enzyme drug to receive FDA approval. Adagen is a PEGylated adenosine deaminase, that is used for the treatment of severe combined immunodeficiency disease (SCID) [86]. Random attachment of multiple linear PEG chains to adenosine deaminase reduced immunogenicity and increased in circulation lifetime.
- †
Supported in part by grants (Nos. RR00080, RR00036, DK20902, and CA38353) from the National Institutes of Health, U.S. Public Health Service.
Copyright © 1988 Published by Mosby, Inc.